Literature DB >> 25827356

Inferring mutational timing and reconstructing tumour evolutionary histories.

Samra Turajlic1, Nicholas McGranahan1, Charles Swanton2.   

Abstract

Cancer evolution can be considered within a Darwinian framework. Both micro and macro-evolutionary theories can be applied to understand tumour progression and treatment failure. Owing to cancers' complexity and heterogeneity the rules of tumour evolution, such as the role of selection, remain incompletely understood. The timing of mutational events during tumour evolution presents diagnostic, prognostic and therapeutic opportunities. Here we review the current sampling and computational approaches for inferring mutational timing and the evidence from next generation sequencing-informed data on mutational timing across all tumour types. We discuss how this knowledge can be used to illuminate the genes and pathways that drive cancer initiation and relapse; and to support drug development and clinical trial design.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer evolution; Intratumour heterogeneity; Mutational timing; Subclonal mutations; Treatment resistance

Mesh:

Year:  2015        PMID: 25827356     DOI: 10.1016/j.bbcan.2015.03.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy.

Authors:  Samra Turajlic; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2015-09-08       Impact factor: 66.675

Review 2.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

3.  Mutational landscape of paired primary and synchronous metastatic lymph node in chemotherapy naive gallbladder cancer.

Authors:  Boqiang Fan; Xianfeng Xu; Xuehao Wang
Journal:  Mol Biol Rep       Date:  2022-01-05       Impact factor: 2.316

4.  Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.

Authors:  Kazuaki Yokoyama; Eigo Shimizu; Nozomi Yokoyama; Sousuke Nakamura; Rika Kasajima; Miho Ogawa; Tomomi Takei; Mika Ito; Asako Kobayashi; Rui Yamaguchi; Seiya Imoto; Satoru Miyano; Arinobu Tojo
Journal:  Blood Adv       Date:  2018-10-09

Review 5.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

6.  The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.

Authors:  Marzieh Armat; Taiebeh Oghabi Bakhshaiesh; Mehdi Sabzichi; Dariush Shanehbandi; Simin Sharifi; Ommoleila Molavi; Jamal Mohammadian; Mohammad Saeid Hejazi; Nasser Samadi
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

7.  Cancer-mutation network and the number and specificity of driver mutations.

Authors:  Jaime Iranzo; Iñigo Martincorena; Eugene V Koonin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-12       Impact factor: 11.205

8.  Predicting clone genotypes from tumor bulk sequencing of multiple samples.

Authors:  Sayaka Miura; Karen Gomez; Oscar Murillo; Louise A Huuki; Tracy Vu; Tiffany Buturla; Sudhir Kumar
Journal:  Bioinformatics       Date:  2018-12-01       Impact factor: 6.937

Review 9.  Building a lineage from single cells: genetic techniques for cell lineage tracking.

Authors:  Mollie B Woodworth; Kelly M Girskis; Christopher A Walsh
Journal:  Nat Rev Genet       Date:  2017-01-23       Impact factor: 53.242

10.  Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model.

Authors:  Paola Lecca; Nicola Casiraghi; Francesca Demichelis
Journal:  Front Genet       Date:  2015-10-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.